Comparison of Survival Between Patients Treated in Five Randomized and One Nonrandomized Multicenter Studies Containing One Arm With IFN-α
| Group . | Median Age (yr) . | % Sokal High Risk . | % Partial + Complete Cytogenetic Responses in IFN Arm . | Aim of Daily IFN Dose at Start of Protocol . | IFN Arm Median Survival (mo) . | Hydroxyurea Arm Median Survival (mo) . |
|---|---|---|---|---|---|---|
| Italian Cooperative Study Group | 48 | 24% | 19% | 5 MIU/m2 | 72 (n = 218) | 52 (n = 104)3-150 |
| German CML Study Group | 47 | 37% | 6%3-151 | 5 MIU/m2 | 66 (n = 133) | 56 (n = 194) |
| MRC CML III, United Kingdom | 52 | 42% | 11% | 3-12 MIU | 64 (n = 152) | 52 (n = 152) |
| Benelux CML Study Group | 56 | 33% | 16% | 2.14 MIU | 64 (n = 100) | 68 (n = 95) |
| CALBG, United States | 44 | Not given | 16%3-152 | 5 MIU/m2 | 66 (n = 107) | |
| French CML Study Group | 51 | 18% | 24% | 5 MIU/m2 | Too early (n = 361) |
| Group . | Median Age (yr) . | % Sokal High Risk . | % Partial + Complete Cytogenetic Responses in IFN Arm . | Aim of Daily IFN Dose at Start of Protocol . | IFN Arm Median Survival (mo) . | Hydroxyurea Arm Median Survival (mo) . |
|---|---|---|---|---|---|---|
| Italian Cooperative Study Group | 48 | 24% | 19% | 5 MIU/m2 | 72 (n = 218) | 52 (n = 104)3-150 |
| German CML Study Group | 47 | 37% | 6%3-151 | 5 MIU/m2 | 66 (n = 133) | 56 (n = 194) |
| MRC CML III, United Kingdom | 52 | 42% | 11% | 3-12 MIU | 64 (n = 152) | 52 (n = 152) |
| Benelux CML Study Group | 56 | 33% | 16% | 2.14 MIU | 64 (n = 100) | 68 (n = 95) |
| CALBG, United States | 44 | Not given | 16%3-152 | 5 MIU/m2 | 66 (n = 107) | |
| French CML Study Group | 51 | 18% | 24% | 5 MIU/m2 | Too early (n = 361) |
All data from the Italian and Benelux group are censored for date of BMT.
Ten percent of the patients used busulfan.
Eight patients, consisting of 6 complete and 2 partial + minor responses.
Partial response was defined by the CALBG group as less than 50% Ph+ metaphases, whereas the other groups took less than 35% as cut-off level.